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Introduction
Glioblastoma multiforme (GBM) is the most common and deadly 
type of malignant brain tumor that affects adults. The patient 
survival rates are low, with less than 5% of patients surviving 5 
years [1,2]. The average life expectancy of patients with GBM is 
only slightly over 1 year, even with current treatment options 
[3]. According to the World Health Organization (WHO), GBM is 
classified into four different tumor grades with class IV being the 
most aggressive and also the most common type of tumor [4]. 
GBM can also be categorized as primary or secondary tumors. 
Even though primary GBM are rapid growing while secondary 
tumors tend to arise slower, they are almost indistinguishable, 
resistant to current available therapies, and have a poor prognosis 
Evaluation of the Anticancer Activity of 
Bioactive Fraction G Extracted from Pavetta 
crassipes in Malignant Brain Tumor Cell Lines
Abstract
Objective: Natural products have served as sources of lead compounds that are 
commonly used in the treatment of human diseases including cancer. Pavetta 
crassipes has been widely demonstrated to have ethnopharmacological potential 
in the management of malaria, gastrointestinal conditions, central nervous system 
behavioral disorders, hypertension, and cancer. The goal of our study was to 
evaluate the biological and molecular effects of Fraction G, obtained from the 
plant Pavetta crassipes, on glioblastoma invasive growth and survival. 
Methodology: The antiproliferative effects of Fraction G, obtained from Pavetta 
crassipes, was evaluated using the trypan blue exclusion, (3-(4, 5-Dimethylthiazol-
2yl)-2, 5-Diphenyltetrazolium Bromide; MTT), and lactate dehydrogenase (LDH) 
assays. Flow cytometry and Western blotting analyses were carried out to examine 
the effects of Fraction G on cell cycle check-points and its effects on epidermal 
growth factor receptor-mediated signaling of AKT and MAPK pathways.
Results: In this paper, we report that the Fraction G obtained from the plant Pavetta 
crassipes induced a reduction in glioma cell viability and proliferation as well as 
induced an increase in apoptosis as evidenced by cleaved PARP, increased caspase 
3/7 activity, and cell cycle arrest in the G0/G1 check point. Furthermore, we report 
that Fraction G inhibited the phosphorylation of AKT and MAPK following EGF 
treatment. 
Conclusion: Taken together, our results demonstrate that Fraction G has potent 
inhibitory effects on pathways involved in glioblastoma proliferation and survival.
Keywords: Glioblastoma; Cancer; Pavetta crassipes; Natural products; 
Ethnopharmacology; Cell proliferation; Apoptosis
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[5]. Dysregulated expression of several important growth factors, 
survival and cell cycle regulators have been implicated as major 
contributing factors to GBM’s invasiveness, rapid growth, and 
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resistance to chemotherapy. Such molecular targets include 
the Epidermal Growth Factor Receptor (EGFR), Platelet Derived 
Growth Factor Receptor (PDGFR), and the Vascular Endothelial 
Growth Factor (VEGF) [6-8]. Overexpression of EGFR occurs in 
about half of primary glioblastoma cases and correlates with 
decreased overall survival of GBM patients. Most brain tumors 
that overexpress EGFR also overexpress the active mutant 
variant, with a frequency of ~40–50%. The mutant form has been 
shown to confer a less favorable prognosis for GBM patients 
[9]. Once dysregulated and activated, it activates downstream 
protein targets, such as PI3K/AKT/mTOR and Ras-Raf-MEK-ERK. 
These signaling pathways are known to promote tumor growth 
and survival [10,11]. Although several treatment options exist, a 
whole host of problems including cost, drug resistance and toxicity, 
and the inability to surgically remove all cancerous cells pose a 
significant barrier to current available therapy and strategies. The 
need for newer effective, and less toxic therapeutic agents and 
strategies cannot be over emphasized. Greater than 50% of drugs 
currently used as chemotherapeutic agents are of natural product 
origin [11] and some of these include Camptotheca alkaloids, 
Vinca alkaloids, Taxus diterpenes, and Podophyllum lignans. 
Natural products of plant and animal sources are known to serve 
as an important source of new chemical entities and drugs with 
potential therapeutic benefits [12]. The research into plants that 
are employed to treat a number of diseases including “cancer” in 
traditional ethnomedicine is therefore one of the productive and 
logical strategies in the search for new therapeutic agents [13]. 
The leaves of the Pavetta crassipes K. Schum (Rubiaceae) plant 
are used for food as well as medicinally in African countries to 
treat a wide variety of diseases and illnesses, such as respiratory, 
cardiovascular, central nervous system and cancer [14-17]. In this 
study, we seek to determine and evaluate the biological effects 
of Pavetta crassipes bioassay guided fractions on malignant 
glioblastoma cells and the molecular signaling pathways 
perturbed by Fraction G.
Materials and Methods
Plant material
The leaves of P. crassipes K. Schum (Rubiaceae) were harvested 
fresh from a horticultural garden in Abuja, FCT, Nigeria, and 
were air-dried. The plant was botanically identified by Dr. Grace 
Ugbabe, and a voucher sample (number 4745) was deposited in 
the department of Medicinal and Traditional Medicine, National 
Institute for Pharmaceutical Research and Development (NIPRD), 
Abuja, Nigeria.
Extraction of plant material
The air-dried leaves were finely powdered, and a 500 g portion 
of the plant material was macerated at room temperature with 
2 L of methanol (MeOH) for 24 hours. The mixture was filtered 
and the filtrate evaporated (40°C) in vacuo until MeOH was 
almost removed. The methanolic extract was dried in a vacuum 
desiccator to yield a dry powder of 75 g.
Bioassay guided fractionation of P. crassipes extracts
Ten grams of the methanolic extract was loaded on a flash 
chromatography column packed with 200 g of silica gel (230-400 
mesh size). The column was successively eluted with petroleum 
ether 100%, petroleum ether/ethyl acetate 7:3; petroleum ether/ 
ethyl acetate 3:7, ethyl acetate 100%, and ethyl acetate methanol 
9:1. Thirty-nine (39) fractions of 50 mL each were collected. 
Fractions were monitored with thin layer chromatography (TLC). 
Fractions showing similar compounds on the TLC were combined. 
Five (5) pooled fractions labeled fraction A, fraction C, fraction E, 
fraction G and fraction J were collected and sent for biological 
screening. Fraction G, eluted with 100% ethyl acetate, was found 
to be biologically active. Fraction G was further analyzed using 
Ultra High Performance Liquid Chromatography (UHPLC).
UHPLC chromatography of fraction G
A Dionex Ultimate 3000 UHPLC instrument equipped with a 
quaternary analytical pump, an autosampler with integrated 
column compartment, a diode array detector, and an automated 
fraction collector was used. Columns utilized included an Acclaim 
120 C18 guard column (4.6 × 10 mm, 5 µm silica) and an Acclaim 
120 C18 analytical column (4.6 × 150 mm, 5 µm silica). The 
mobile phase was composed of 65% methanol and 35% water 
(containing 1% glacial acetic acid). The sample was dissolved in 
the mobile phase at a concentration of 1 mg/mL. The analysis 
was performed at a temperature of 30°C, flow rate of 1.0 mL/min 
and injection volume of 10 µL. Peaks were monitored at 223, 230, 
254 and 365 nm.
Cell lines
Human glioblastoma cell lines (U251 MG, U1242 MG) and 
Normal Human Astrocytes (NHAs) were kind gifts from Dr. Isa 
Hussaini, University of Virginia, Charlottesville, USA. The cells 
were cultured in MEM-alpha (Life Technologies, Fisher Scientific, 
Pittsburgh, PA), supplemented with 10% FBS (Biowest, Kansas, 
MO), 1% penicillin and streptomycin (Fisher Scientific, Pittsburgh, 
PA). Prior to experimental studies and assays, cultures were 
grown to 70-80% confluency. These cells were serum starved and 
treated with Fraction G in the presence or absence of EGF (25 ng/
mL).
Chemicals and reagents
EGF and anti-tubulin antibody (DM1A) were purchased from 
Sigma Aldrich (St. Louis, MO), phospho-specific and total 
antibodies directed against ERK ½, and AKT, were obtained from 
Cell Signaling Technologies (Beverly, MA), antibody directed 
against PARP was obtained from Trevigen (Gaithesburg, MD). MTT 
(3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide) 
was purchased from Promega (Madison, WI). 0.4% Trypan blue 
stain was obtained from Gibco Life Technologies (Grand Island, 
NY). Pierce LDH cytotoxicity assay kit was obtained from Thermo 
Scientific (Rockford, IL).
Cell counts using Trypan blue exclusion assay
GBM cell lines U251 MG and U1242 MG were seeded at 1 × 
105 cells per well in a 6 well plate in the presence or absence 
of Fraction G (0-20 µg/mL) for 0-72 h. Treated and untreated 
cells were trypsinized and harvested every 24 h. 100 μL of cell 
suspension was pipetted into a microcentrifuge tube and mixed 
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with 100 μL of Trypan blue dye. 20 μL of cell suspension was 
added to a hemocytometer slide and the cells were counted 
under a microscope [18]. In another set of experiments, we 
tested the effects of Fraction G on non-malignant, normal human 
astrocytes (NHA). NHAs were grown on glass slides in a 6 well 
plate. After reaching 70% confluency, the cells were treated with 
DMSO (control) and Fraction G (10 µg/mL) for 48 h. The cells 
were washed with PBS and photographed using a NIKON H600L 
Eclipse, Japan fluorescence microscope.
Assessment of cell viability
This test was carried out to assess the effects of fraction G on 
glioma cell proliferation using the MTT assay. The MTT assay is 
based on the ability of cells to metabolize a yellow tetrazolium 
salt to a formazan product that can be detected using a 
spectrophotometer. Briefly, GBM cells were seeded at 5 × 103 
cells in a 96-well plate and incubated for 24 h. The cells were 
then treated with various concentrations of Fraction G (0-20 
µg/mL) for 48 and 72 h. Following Fraction G exposure, 20 µL 
of MTT reagent was added to the 96-wells containing cells and 
culture media (100 µL) and the plates were incubated at 37 °C 
in a humidified atmosphere containing 5% carbon dioxide for 4 
h. At the end of the 4 h incubation period, the cell solubilization 
and stop reagent was added at a volume of 100 µL for 60 min., 
kept in the dark at room temperature and the optical density 
was measured using Promega Glomax Multidetection System 
(Madison, WI). The optical density was used to calculate the rate 
of cell proliferation after exposure to the different concentrations 
of Fraction G compared to the control wells. All experiments were 
performed in triplicate and the mean ± SEM for each experiment 
was calculated and plotted as a bar graph [19,20].
Cell cycle analysis by flow cytometry
The flow cytometric analysis of U251 glioma cells was performed 
using the Becton Dickinson FACScalibur (BD Biosciences, San 
Jose, CA) equipped with CellQuest software. U251 MG cells were 
plated in 10 cm plates. After 24 h the cells were serum starved and 
treated with varying concentrations of Fraction G (0-20 µg/mL) 
for 72 h. After the 72 h treatment, the floating and adherent cells 
were pooled together. The cell suspension was then centrifuged 
at 800 x g. Cell pellets were resuspended, washed with PBS, fixed 
in ice-cold 70% ethanol and stored at -20°C. The fixed cells were 
washed with PBS and stained with a solution consisting of PBS 
with 20 µg/mL of propidium iodide from Sigma, (St. Louis, MO), 
0.1% Triton X-100 and 200 µg/mL RNAse A (Sigma, St. Louis, MO), 
kept in the dark for 1 h. The stained cells were analyzed using 
the BD FACScalibur equipped with CellQuest software. For each 
sample 20,000 counts were analyzed. Cells were gated using the 
Cellquest software to estimate the proportion of cells distributed 
as a percentage in the different cell cycle compartments [21].
Detection of apoptotic cells
Living and dead glioma cells were detected using fluorescence 
microscopy. In this assay, GBM cells were cultured on coverslips 
and treated with varying concentrations of Fraction G (0, 5-20 
µg/mL) for 72 h. At the end of the treatment time point, cells 
were washed with PBS and stained with the Hoechst 33342 (10 
µg) for live cells and PI (10 µg) for dead cells. Hoechst 33342 dye 
penetrates the membrane and therefore, has the potential to 
stain live cells. This stain is known to bind the adenine-thymine-
regions of the DNA. The fluorescence of Hoechst dye is very 
sensitive to DNA changes in cells. This dye can detect changes of 
nuclear compromise and damage. Hoechst 33342 dye emits blue 
fluorescence when bound to double-stranded DNA. This dye is 
often used to distinguish condensed nuclei in apoptotic cells. The 
propidium iodide dye is an impermeant dye that is often excluded 
from the living and viable cells. PI dye is known to penetrate cells 
with compromised or damaged membrane. The stained cells 
were placed in the dark for 10 min at room temperature. Images 
of cells were photographed using the NIKON H600L Eclipse, Japan 
fluorescence microscope [22,23].
Lactate Dehydrogenase (LDH) assay
The release of lactate dehydrogenase (LDH) is indicative of 
compromised membrane integrity and cell injury. The assay 
protocol outlined by Trevor et al. [24] was used in this study with 
some modifications. GBM cells (U251 MG and U1242 MG) were 
treated with Fraction G for 48 h. After treatment, cellular amount 
of LDH was measured by adding lysis buffer (1% Triton) to the cells. 
The amount of LDH content released by the cells was measured 
using Promega Glomax Multi-detection system microplate reader 
at a wavelength of 490 nm. The data obtained are represented as 
mean ± SEM of three independent experiments.
Measurement of caspase 3/7 activity
Caspase activity was detected as a means to evaluate apoptosis 
in cells treated with fraction G. Cells were assayed for Caspase 
3/7 activity 48 h after fraction G treatment using Caspase 3/7 
Glo substrate solution as recommended by the manufacturer 
(Promega, Madison, WI). Luminescence was measured using 
a Glomax multidetector system (Promega, Madison, WI). 
Luminescence readings were corrected by cell number and also 
compared to protein concentration via BCA (Thermo Scientific 
(Rockford, IL). Values shown are normalized to a percent maximal 
activity. In another set of experiments, a broad spectrum caspase 
inhibitor was used to rescue the effect of fraction G on up-
regulation of caspase cleavage. Glioma cell lines were pretreated 
with the caspase inhibitor Ac-DEVD-CHO (100 µM) for 4 hours 
and then treated with fraction G for 48 h. After a 48 h time point, 
the cells were counted using the hemocytometer.
Western blot analysis
Immunoblotting analyses were carried out as previously reported 
[25,26]. After the different treatments, cells were washed in ice 
cold PBS and extracted with 1% Triton X-100 cell lysis buffer. 
Cells were centrifuged at 14,000 x g for 10 min at 4°C. Protein 
concentrations of the supernatant were determined by the BCA 
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protein assay (Bio-Rad). Proteins were subjected to electrophoresis 
and separated by SDS-PAGE on 10% polyacrylamide gels and then 
electroblotted onto nitrocellulose. The nitrocellulose membranes 
were incubated with primary antibody overnight at 4°C. These 
membranes were washed three times with phosphate buffered 
saline with tween 20 (PBST) and incubated with a peroxidase 
conjugated secondary antibody (Jackson ImmunoResearch Lab, 
West Grove, PA) at room temperature. After the secondary 
antibody, the membranes were washed and protein visualization 
was carried out using the enhanced chemiluminescence (ECL) 
reagents from Fisher Scientific (Milwaukee, WI) as described 
by the manufacturer. In sets of experiments investigating 
PARP cleavage, glioma cell lines were treated with different 
concentrations of fraction G, floating cells as well as the adherent 
cells were pooled together and centrifuged at 800 × g. The media 
was decanted and the cell pellet was extracted with RIPA buffer. 
The cell suspension was then sonicated and centrifuged at 14,000 
× g for 10 min at 4 °C. Proteins (20 µg/lane) were separated by 
SDS-PAGE on 10% or 12% polyacrylamide gels, then transferred 
onto nitrocellulose and reacted with antibodies directed against 
PARP. Experiments were repeated three times for reproducibility. 
Densitometry and ImageQuant were carried out using the Alpha 
Innotech FluorChem2 (Cell Biosciences, Santa Clara, CA).
Statistical analysis
Data are expressed as mean ± SEM. All statistical analyses were 
performed with GraphPad Prism 7 software using the one-way 
analysis of variance followed by the Bonferroni test. A value of 
p<0.05 was considered to be statistically significant.
Results
HPLC analysis of fraction G
The HPLC finger print data revealed that Fraction G was a mixture 
of several compounds as seen in Figure 1.
Effect of fraction G from Pavetta crassipes leaves 
on glioma cell proliferation
We employed the MTT assay to determine the effects of Fraction G 
on GBM cell proliferation and viability. The MTT assay is based on 
the cells ability to convert tetrazolium salt to insoluble formazan. 
A decrease in cellular accumulation of formazan indicates a 
damage in cells (loss of viable cells) or cytostatic activity. Our 
results revealed that fraction G induces a dose-dependent 
decrease in the formation of formazan by the glioma cell lines 
tested (U251 MG (Figure 2A) and U1242 MG (Figure 2B)). EGF 
is known to stimulate pathways that increase cell proliferation, 
survival and migration in glioblastoma. We tested the effects of 
Fraction G on EGF induced cell proliferation and viability using 
the MTT assay in GBM cells. The addition of 25 ng/mL EGF 
induced a robust increase in GBM cell proliferation. Fraction G 
concentration-dependently abrogated EGF-mediated increase in 
cell proliferation in U251 (Figure 2C) and U1242 (Figure 2D).
Effect of fraction G from Pavetta crassipes leaves 
on glioma cell viability
The MTT test above suggests that Fraction G decreased the 
viability of U1242 MG and U251 MG cells. To confirm these 
effects, we examined the effects of Fraction G on U1242 MG and 
U251 MG cell viability using the Trypan blue exclusion and lactate 
 
Figure 1 Chromatogram of Fraction G from Pavetta crassipes extracts.
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Figure 2 Effects of fraction G (0-20 µg/mL) on the proliferation of (a) U251 MG cells as measured by a MTT assay after 48 h of treatment. (b). 
Effects of fraction G (0-20 µg/mL) on the proliferation of U1242 MG cells as measured by a MTT assay after 48 h of treatment. (c). 
Effects of fraction G (0-20 µg/mL) on EGFR-mediated cell proliferation in U251 MG cells. (d). Effects of fraction G (0-20 µg/mL) on 
EGFR-mediated cell proliferation in U1242 MG. All data are expressed as the mean ± SD of experiments. *Denotes significant (p<0.05) 
difference in proliferation of treated cells compared to untreated control cells.
dehydrogenase (LDH) assays. Trypan blue exclusion is based on 
the principle that live cells possess intact cell membranes and 
will exclude trypan blue, while dying cells possess compromised 
cell membranes and thus will not exclude dye. We observed that 
both U1242 MG and U251 MG treated with Fraction G (0-20 
µg/mL) showed a dose- and time-dependent increase in trypan 
blue positivity (Figure 3A and 3B) compared with cells treated 
with control medium. We also tested the ability of fraction G to 
cause changes in cell membrane integrity and leakage of lactate 
dehydrogenase (LDH) into extracellular media on U1242 MG and 
U251 MG. U1242 MG and U251 MG cells treated with Fraction 
G dose-dependently displayed an increased in the amount of 
lactate released into culture media after 48 h when compared 
to control cells (Figure 3C and 3D). Our data shows that Fraction 
G dose dependently decreased GBM cell viability. Futhermore, 
we investigated the effects of Fraction G on the viability of non-
malignant normal human astrocytes. We observed from the 
pictograph that treatment with fraction G (10 µg/mL) did not 
alter the morphology of the cells (Figure 3E).
Effect of fraction G from Pavetta crassipes leaves on 
glioma cell cycle
Since the MTT test does not distinguish cellular proliferation from 
death, we employed cellular number counts and fluorescent 
activated cell sorting (FACS) to ascertain the effects of Fraction G on 
GBM cell cycle check points. Flow cytometric analysis revealed that 
Fraction G significantly increased the percentage of cells arrested in 
G0/G1 cell cycle check point with fragmented nuclei when compared 
to control treated cells (Figure 4A). Our data showed that 18.94% of 
control cells were arrested while cells treated with Fraction G had 
an increase in arrested cells from 33.81% to 41.8% (Figure 4A). 
We further tested the effects of Fraction G on U251 MG cells 
and imaged both the dead and living cells using the Hoechst 
33342 and propidium iodide. Our data in Figure 4B illustrates an 
increase in the number of cells incorporating propidium iodide 
with increase in the concentration of Fraction G.
The effect of fraction G from Pavetta crassipes 
leaves on GBM cell death
To ascertain the mechanism of cell death induced by Fraction G 
in U1242 MG and U251 MG cells, we measured PARP cleavage, a 
well-known hallmark of apoptosis (33). We observed an increase 
in the cleaved form of PARP from the active 116-kda DNA repair 
molecule to the inactive 89-kda molecule in GBM cells treated 
with a higher concentration of Fraction G when compared to 
control cells (Figure 5A and 5B). Our data shows that Fraction 
G induced apoptotic-dependent cell death of GBM cells. We 
further investigated the effects of caspase activity, we show 
here that fraction G induces a concentration dependent increase 
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Figure 3 Effects of fraction G (0-20 µg/mL) on the viability of (a). U 251 MG cells after 24, 48 and 72 h of treatment (b). Effects of fraction G 
(0-20 µg/mL) on the viability of U1242 MG cells after 24, 48, 72 h of treatment. (c) Cytotoxicity of fraction G (0-20 µg/mL) in U251 
MG cells and (d) U1242 MG as measured by a LDH assay after 48 hours of treatment. (e) Pictograph showing the effects of Fraction 
G on non-malignant NHA cells. All data are expressed as the mean ± SD of experiments performed in triplicate. *Denotes significant 
(p < 0.05) difference in cell death in treated cells compared to untreated.
in caspase activity (Figure 5C and 5D). Our data also revealed 
that both U1242 MG cells and U251 MG cells were sensitive to 
Fraction G treatment. We attempt to rescue the observed cell 
death induced by fraction G in glioma cell lines by pretreating the 
cells with caspase inhibitor Ac-DEVD-CHO. Our data in Figure 5E 
showed that pretreatment with the caspase inhibitor abrogated 
the decrease in cell counts induced by fraction G.
The effect of fraction G from Pavetta crassipes 
leaves on EGF-mediated activation of AKT and ERK 
½ in GBM cells
To investigate the molecular mechanisms by which Fraction G 
induces cell death and inhibits proliferation in GBM cells, we 
investigated the effects of fraction G on EGF mediated activation 
of MAPK and AKT. EGF binding to EGFR activates the Ras-Raf-
MEK-ERK pathway which phosphorylates and activates ERK ½ 
downstream. AKT is activated by EGF through the PI3K/AKT/
mTOR pathway. Once activated, both AKT and ERK ½ can activate 
other downstream signaling proteins that reduce apoptosis 
and promote cell survival. Western blot analyses of U1242MG 
and U251 MG cells treated with Fraction G attenuated EGFR-
mediated phosphorylation of AKT (Figure 6A and 6C) and ERK ½ 
(Figure 6B and 6D) in a concentration-dependent manner. These 
data suggest that Fraction G interferes with EGF mediated effects 
on the GBM cells by inhibiting the activation of ERK ½ and AKT.
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Figure 4 (A) Flow cytometry analyses for U251 MG cells treated with fraction G (0-20 µg/mL). After 72 hours, the cells were then stained with 
propidium iodide and subjected to flow cytometry to analyze the cell cycle distribution. The table (insert) showed the percentage of 
cells arrested at the G0/G1 cell cycle check point. (B) Effects of fraction G (0-20 µg/mL) on the morphology of U251 MG cells stained 
with both propidium iodide and HOECHST 33342 (Magnification X10).
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Figure 5 (A) Western blot analyses showing the effects of fraction G (0-20 µg/mL) on the expression of cleavage of PARP in U251 MG cells 
and (B) U1242 MG cells. Effects of fraction G on caspase 3/7 activity on (C) U1242 MG and (D) U251 MG cells after 48 h treatment. 
(E) Effects of caspase inhibitor Ac-DEVD-CHO on U1242 MG and U251 MG cells treated with fraction G.
 
Figure 6 Western blot analyses showing the effects of fraction G (0-20 µg/mL) on EGF-induced phosphorylation of AKT in (A) 
U251 MG and (C) U1242 MG cell lines. Western blot analyses showing the effects of fraction G (0-20 µg/mL) on EGF-
induced phosphorylation of ERK1/2 in (B) U251 MG and (D) U1242 MG cell lines.
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Discussion
Medicinal plants have been used traditionally over the years 
to treat several disease conditions and are still being used. The 
resistance of cancer cells to current available chemotherapeutic 
agents and the toxic side effects of these agents has prompted 
scientists to further investigate the therapeutic potential of 
natural agents. Even though many extracts from plants are 
being investigated for their potential biological activities, it is 
increasingly evident that the efficacy of these products require 
their presence in a mixture of complex molecules rather than in 
a pure single state [27,28]. With this thought in mind, we sought 
to investigate the anticancer activity of Fraction G extract from 
Pavetta crassipes leaves. We have previously reported that the 
extract from Pavetta crassipes leaves possess some biological 
CNS activities [16]. In this study we demonstrated that Fraction 
G extract from Pavetta crassipes leaves has antitumor activity 
against GBM cells, via its anti-proliferation, survival and its 
potential to induce apoptosis. The anti-proliferative properties 
of Fraction G occurred via the accumulation of these cells in the 
G0/G1 phase of the cell cycle, while its pro-apoptotic properties 
will most likely be through caspase activation since we observed 
PARP cleavage. The ability of Fraction G to induce apoptosis as 
preferred cell death makes it a potential tool for GBM therapy. 
Various small molecules and therapeutic antibodies targeting 
EGFR family members have been developed and are currently 
used in the treatment of GBM. However, the increased use of 
EGFR tyrosine kinase inhibitors has led to the development of 
resistance to EGFR-targeting drugs due to targeted mutations and 
the presence of EGFR-mutated variants. EGFR signaling plays a 
key role in many cancers including glioblastoma. EGFR activation 
of the RTK/RAS/PI3K pathway aids in the regulation of cellular 
proliferation, angiogenesis, local tissue invasion and resistance to 
apoptosis [29]. AKT provides key regulation of several cell survival, 
growth and proliferation pathways. Additionally, changes in the 
AKT pathway appear to play key roles in many types of cancer. 
Thus this pathway has become a signaling pathway of interest to 
target for cancer treatment [30]. Our data revealed that Fraction 
G inhibited EGF mediated phosphorylation of AKT in glioma cell 
lines. This data agrees with several studies that have shown 
natural products downregulate AKT phosphorylation in gastric, 
breast, brain, and other cancer cell lines [8,31]. Additionally, 
the ERK pathway, one of several MAPK pathways, is known for 
its role in cell proliferation. However, it is also understood to be 
involved in other aspects of tumor presentation such as cellular 
differentiation and migration [32-34]. Here we show that Fraction 
G extract from Pavetta crassipes leaves inhibited EGF-mediated 
ERK ½ phosphorylation.
Conclusion
The present study demonstrated that Fraction G possesses in vitro 
biological activity against GBM cells by inhibiting cell proliferation 
and inducing apoptosis. Our data also demonstrate that Fraction 
G attenuated EGF-mediated phosphorylation of ERK ½ and AKT. 
Additionally, we observed that treatment with Fraction G induced 
PARP cleavage in two genetically different GBM cells. Fraction 
G extract exhibited a dose and time dependent inhibition of 
EGF mediated GBM cell survival and proliferation. Therefore, 
we conclude that Fraction G of the leaf extracts of P. crassipes 
possess anti-tumor effects which possibly may be mediated via 
the inhibition of AKT and ERK ½ signaling pathways and induction 
of PARP cleavage.
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